Harvard Bioscience Inc. 8-K Summary
Business Context and Reporting Period
Harvard Bioscience, Inc. (HBIO) filed this Current Report on Form 8-K on November 3, 2021. The filing announces the release of financial results for the three months ended September 30, 2021, and details a related conference call held on the same date.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release furnished as Exhibit 99.1, which is incorporated by reference but not detailed in the body of this 8-K document.
Material Changes
No specific material changes versus the prior comparable period are quantified in this filing text. The document serves solely to notify investors of the availability of the Q3 2021 results.
Guidance, Outlook, and Risks
The filing does not contain specific guidance, outlook, management commentary, or risk factors. It references a press release (Exhibit 99.1) for the full details of the results and conference call. The filing includes a standard disclaimer that the information in Item 2.02 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for actual Q3 2021 revenue, net income, and cash flow figures.
- Verify the details of the conference call held on November 3, 2021, for management commentary on the results.
- Check subsequent filings (10-Q) for audited or reviewed financial statements corresponding to the period ended September 30, 2021.
- Confirm the trading symbol (HBIO) and exchange (NASDAQ) for current market data.